4月25日，有报道称，湖南汉森制药的四磨汤中的一味成分槟榔，在2003年被世界卫生组织的国际癌症研究中心(IARC)认定为一级致癌物。同一天，汉森制药宣布临时停牌。昨天复牌即跌停，报20.09元/股，跌幅为9.99%。

4月25,,There have been reports,Hunan Hansen pharmaceutical four grind blindly ingredients in the soup of betel nut,In 2003 by the world health organization's international agency for research on cancer(The IARC)Identified as carcinogens.On the same day,Hansen pharmaceutical announced a temporary suspended.Resumption of the drop stop yesterday,20.09 yuan/share,A 9.99% drop.

　　昨天，汉森制药首度对此事作出回应。汉森制药董秘向京华时报记者明确表示：四磨汤不具致癌性。他表示，槟榔为四磨汤的一味药材，为四大南药之一，一直收录于《中国药典》。报道中，IARC在2003年8月7日特别刊物第85卷中，认定槟榔为一级致癌物。经查证，原文是针对咀嚼槟榔与人类口腔癌、食道癌、咽喉癌之间联系的综述，显示咀嚼槟榔因槟榔中的成分在口腔内发生酶代谢，产生氮氧化合物，刺激口腔，可能诱发口腔癌。

yesterday,Hansen pharmaceutical for the first time to respond to this matter.Hansen pharmaceutical chairman secretary made it clear to the Beijing times press:Four grind soup has no carcinogenicity.He said,Betel nut for four grind soup blindly medicine,As one of the four big NaYao,Has been included in[The Chinese pharmacopoeia].In the report,The The IARC in August 7, 2003, special publication 2003 volume,As betel nut for level 1 carcinogen.Through the verification,The original is for chewing areca and human oral cancer/Esophageal cancer/Connections between throat cancer were reviewed,According to chew betel nut in penang elements metabolism enzyme in the mouth,Produce nitrogen oxides,Stimulate the oral cavity,May cause oral cancer.

　　“四磨汤口服液的槟榔用药部位为成熟干燥种子，而咀嚼槟榔为幼果，取用部位与使用方法完全不同。中成药处方中含槟榔的品种较多，其中有多种小儿用药，至今未见致癌性报道。”汉森制药相关负责人说。

"Four grind soup oral liquid of betelnut use parts for mature, dry seeds,Chewing betel nuts for young fruit,Taking place and method of use is totally different.Proprietary Chinese medicine prescription contains areca varieties more,There are a variety of pediatric drug use,The carcinogenicity reports yet."The relevant person in charge of Hansen pharmaceutical said.

　　湖南益阳市食品药品监督管理局昨天表示，相关药品的日常检测没有问题，如果消费者不放心可自行送检。

湖南益阳市食品药品监督管理局yesterday表示,Related drugs daily test no problem,If consumers don't trust can be inspection on its own.

　　记者查阅国家食品药品监管总局官网发现，其他上市公司产品原料涉及槟榔的有：北京同仁堂的木香槟榔丸、华润三九黄石药业公司的木香槟榔丸、哈药集团三精黑河药业的槟榔四消片等。上述公司证代均表示，公司如有需要披露之信息会按相关规定进行披露。“公司所生产药品均符合国家标准。”北京同仁堂对记者表示。昨天，同仁堂、华润三九和哈药股份的股价分别跌1.58%、4.29%和0.94%。当日，医药板块下跌1.68%。

记者查阅国家食品药品监管总局官网发现,Other products raw materials relating to the betel nut has a listed company:Beijingtongrentang的木香槟榔丸/Huarun san-jiu Yellowstone pharmaceutical company's combination of betel nuts pill/Yongjiaxian sanjing heihe of Harbin pharmaceutical group pharmaceutical betel nut elimination, etc.Company card to all said above,Company if there is a need to disclose the information will be disclosed according to related regulations."Company produces drugs all meet the national standards."Beijingtongrentang对记者表示.yesterday,tongrentang/China resources and lump-sum pharm co shares fell 1.58%, respectively/4.29% and 0.94%.On the day,Pharmaceutical sector fell by 1.68%.